Möchten Sie immer auf dem neuesten Stand bleiben?

SÃO PAULO, BRAZIL, May 11, 2026 (GLOBE NEWSWIRE) -- J&F S.A. (the “Company”) today announced the expiration and final results of its previously announced offer by its subsidiary J&F...

Management to host conference call on Tuesday, May 12, 2026, at 4:30 PM ET PINE MOUNTAIN, Georgia, May 11, 2026 (GLOBE NEWSWIRE) -- Parks! America, Inc. (OTCQX: PRKA), today announced its financial...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the...

First Quarter 2026 and Selected Highlights:  VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand...

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...

Net Revenue increased 4.5% to $312.0 millionGAAP Net Income increased 188.6% to $1.4 millionAdjusted Net Income decreased 3.6% to $3.4 millionAdjusted EBITDA increased 3.8% to $ $10.1 million LAS...

SHAKOPEE, Minn., May 11, 2026 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC), today reported financial results for the first quarter ended...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent...

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors ...

New York, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape |...